한글목차

알파 지중해 빈혈 치료제 세계 시장 규모는 2024년 10억 7,000만 달러에 달했고, 예측 기간 동안 6.76%의 연평균 복합 성장률(CAGR)로 2030년까지 강력한 성장이 예상됩니다.

세계 시장 상황은 진행 중인 연구, 진화하는 치료법, 그리고 특히 지중해 빈혈 유병률이 높은 지역에서 큰 질병 부담을 특징으로 하는 복잡하고 역동적인 양상을 보이고 있습니다. 알파 지중해 빈혈은 알파 글로빈 유전자의 돌연변이로 인해 알파 글로빈 사슬의 생산이 감소하거나 결여되는 유전성 혈액 질환입니다. 그 결과 적혈구 내 산소 운반을 담당하는 단백질인 헤모글로빈의 생산 균형이 깨져 빈혈 및 기타 건강상의 합병증을 유발합니다. 알파 지중해 빈혈 시장은 몇 가지 요인에 의해 주도되고 있습니다. 첫째, 알파 지중해 빈혈을 포함한 지중해 빈혈의 전 세계 유병률은 상대적으로 높으며, 특히 지중해 주변 국가, 중동, 동남아시아, 아프리카 일부 지역에서 높은 유병률을 보이고 있습니다. 이러한 높은 유병률은 진단과 치료가 필요한 상당한 수의 환자 집단을 만들어 냈습니다. 유전자 검사 및 진단 기술의 발전으로 알파 지중해 빈혈 진단의 정확성과 접근성이 향상되어 시장 성장에 기여하고 있습니다. 예를 들어, NCBI에 게재된 2024년 논문에 따르면 전 세계 인구의 약 5%가 알파 지중해 빈혈 형질을 가지고 있다고 합니다. 이 질환의 임상적으로 중요한 유형은 동남아시아에서 가장 널리 퍼져 있습니다.

시장 성장 촉진요인

특정 지역의 높은 유병률

주요 시장 이슈

제한적 인지도 및 검진 프로그램

주요 시장 동향

유전자 검사의 발전

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 알파 지중해빈혈 치료 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별(알파 지중해빈혈 사일런트 캐리어, 알파 지중해빈혈 캐리어, 헤모글로빈 H 질환, 알파 지중해빈혈 메이저)
  • 치료별(엽산 보충제, 철 킬레이트제, 수혈, 줄기세포 이식)
  • 최종사용자별(병원 및 진료소, 외래 진료 센터, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵
  • 유형별
  • 치료별
  • 최종사용자별
  • 지역별

제5장 아시아태평양의 알파 지중해빈혈 치료 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별
  • 치료별
  • 최종사용자별
  • 국가별
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 호주
  • 일본
  • 한국

제6장 유럽의 알파 지중해빈혈 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제7장 북미의 알파 지중해빈혈 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 멕시코
  • 캐나다

제8장 남미의 알파 지중해빈혈 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 아르헨티나
  • 콜롬비아

제9장 중동 및 아프리카의 알파 지중해빈혈 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트(UAE)

제10장 시장 역학

• 성장 촉진요인
• 과제

제11장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병(M&A)

제12장 세계의 알파 지중해빈혈 치료 시장 : SWOT 분석

제13장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제14장 경쟁 구도

• Agios Pharmaceuticals, Inc.
• Actis Technologies
• Novartis Pharmaceuticals Corporation
• Global Calcium PVT LTD
• CHIESI Farmaceutici S.p.A.
• Taro Pharmaceutical Industries Ltd.
• Amgen Inc.
• Sun Pharmaceutical Industries Ltd.
• FRESENIUS SE & Co. KGaA
• Acceleron Pharma.

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

영문목차

Global Alpha Thalassemia Treatment Market was valued at USD 1.07 billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 6.76% through 2030. The Global Alpha Thalassemia Treatment Market presents a complex and dynamic landscape characterized by ongoing research, evolving treatment modalities, and a significant burden of disease, particularly in regions with a high prevalence of thalassemia. Alpha thalassemia is a hereditary blood disorder caused by mutations in the alpha-globin genes, resulting in reduced or absent production of alpha-globin chains. This leads to an imbalance in the production of hemoglobin, the protein responsible for carrying oxygen in red blood cells, causing anemia and other health complications. The market for alpha thalassemia is driven by several factors. Firstly, the global prevalence of thalassemia, including alpha thalassemia, is relatively high, especially in countries around the Mediterranean, the Middle East, Southeast Asia, and parts of Africa. This high prevalence creates a substantial patient population in need of diagnosis and treatment. Advancements in genetic testing and diagnostic technologies have improved the accuracy and accessibility of alpha thalassemia diagnosis, contributing to market growth. For instance, according to a 2024 article published in NCBI, around 5% of the global population carries the a-thalassemia trait. Clinically significant forms of the disorder are most prevalent in Southeast Asia.

Key Market Drivers

High Prevalence in Certain Regions

The high prevalence of alpha thalassemia in certain regions plays a pivotal role in boosting the Global Alpha Thalassemia Treatment Market. This hereditary blood disorder exhibits a notably elevated occurrence in specific geographic areas, primarily encompassing countries around the Mediterranean, the Middle East, Southeast Asia, and certain parts of Africa. In these regions, the frequency of genetic mutations responsible for alpha thalassemia is significantly higher compared to other parts of the world. This elevated prevalence results in a substantial and enduring patient population, driving the demand for diagnostic tests, therapeutic interventions, and comprehensive disease management solutions. For instance, according to a 2023 article published in NCB, alpha thalassemia mutations are highly prevalent in the Mediterranean and Middle Eastern regions. Research based on previous studies indicates that up to 40% of individuals in these populations carry the genetic mutation associated with the disorder. This high carrier rate contributes to an increased incidence of clinically significant alpha thalassemia cases in these regions. The findings highlight the need for enhanced genetic screening, early diagnosis, and effective management strategies to address the impact of alpha thalassemia in affected populations.

Key Market Challenges

Limited Awareness and Screening Programs

Alpha thalassemia is a genetic blood disorder that affects the production of hemoglobin, leading to anemia and other health complications. It is particularly prevalent in regions with a high prevalence of consanguineous marriages, such as Southeast Asia, the Middle East, and parts of Africa. While significant strides have been made in the field of healthcare, the global alpha thalassemia treatment market faces a critical obstacle: limited awareness and inadequate screening programs.

One of the primary challenges in tackling alpha thalassemia is the lack of awareness about the disease among the general population. Many individuals in high-risk regions are unaware of their carrier status, which means they could pass the genetic mutation to their offspring unknowingly. This lack of awareness perpetuates the cycle of alpha thalassemia within affected communities and contributes to the disease's persistence.

The absence of comprehensive screening programs exacerbates the problem. Screening for alpha thalassemia is crucial for early detection and genetic counseling, which can help individuals make informed decisions about family planning. However, in many regions, screening programs are either non-existent or inadequately funded, limiting their reach and effectiveness. This results in a missed opportunity to identify carriers and provide them with the necessary information and support.

Key Market Trends

Advancements in Genetic Testing

Advancements in genetic testing have played a pivotal role in boosting the global alpha thalassemia treatment market. This progress in diagnostic technology has revolutionized the way healthcare professionals identify and manage alpha thalassemia, significantly improving patient outcomes. With the advent of advanced genetic testing methods, it has become possible to pinpoint the specific genetic mutations responsible for alpha thalassemia accurately. Traditional diagnostic methods relied on general blood tests and clinical symptoms, which often led to delayed or inaccurate diagnoses. However, the introduction of DNA-based tests, including polymerase chain reaction (PCR) and DNA sequencing, has allowed for the precise identification of alpha thalassemia mutations. These tests can distinguish between different subtypes of the disease, such as alpha thalassemia minor (carrier status) and more severe forms like hemoglobin H disease or Bart's hydrops fetalis syndrome.

The benefits of these advancements are multifold. Firstly, they enable early and accurate diagnosis of alpha thalassemia, which is crucial for initiating timely interventions and genetic counseling. Secondly, these tests provide essential data for assessing disease severity and tailoring treatment plans to individual patients, optimizing the management of alpha thalassemia. The genetic testing has become an invaluable tool for family planning, helping at-risk couples make informed decisions about having children.

From a research and drug development perspective, the detailed genetic information obtained through these tests has opened up new avenues for targeted therapies. Researchers can now explore precision medicine approaches, developing treatments that address the specific genetic mutations responsible for each patient's condition. This has the potential to lead to more effective and less invasive treatments for alpha thalassemia.

Advancements in genetic testing have facilitated large-scale epidemiological studies, providing a clearer picture of the global prevalence and distribution of alpha thalassemia. This data is essential for healthcare policymakers and organizations to allocate resources effectively, implement screening programs, and improve access to care for affected populations.

Key Market Players

• Agios Pharmaceuticals, Inc.
• Actis Technologies
• Novartis Pharmaceuticals Corporation
• Global Calcium Pvt. Ltd.
• CHIESI Farmaceutici S.p.A.
• Taro Pharmaceutical Industries Ltd.
• Amgen Inc..
• Sun Pharmaceutical Industries Ltd.
• FRESENIUS SE & Co. KGaA
• Acceleron Pharma

Report Scope:

In this report, the Global Alpha Thalassemia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Alpha Thalassemia Treatment Market, By Type:

• Alpha Thalassemia Silent Carrier
• Alpha Thalassemia Carrier
• Hemoglobin H Disease
• Alpha Thalassemia Major

Alpha Thalassemia Treatment Market, By Treatment:

• Folic Acid Supplement
• Iron Chelators
• Blood Transfusion
• Stem Cell Transplant

Alpha Thalassemia Treatment Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Alpha Thalassemia Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Alpha Thalassemia Treatment Market.

Available Customizations:

Global Alpha Thalassemia Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Alpha Thalassemia Treatment Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Alpha Thalassemia Silent Carrier, Alpha Thalassemia Carrier, Hemoglobin H Disease, Alpha Thalassemia Major)
  • 4.2.2. By Treatment (Folic Acid Supplement, Iron Chelators, Blood Transfusion, Stem Cell Transplant)
  • 4.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By Treatment
  • 4.3.3. By End User
  • 4.3.4. By Region

5. Asia Pacific Alpha Thalassemia Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Treatment
  • 5.2.3. By End User
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Alpha Thalassemia Treatment Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By Treatment
      • 5.3.1.2.3. By End User
  • 5.3.2. India Alpha Thalassemia Treatment Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By Treatment
      • 5.3.2.2.3. By End User
  • 5.3.3. Australia Alpha Thalassemia Treatment Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By Treatment
      • 5.3.3.2.3. By End User
  • 5.3.4. Japan Alpha Thalassemia Treatment Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By Treatment
      • 5.3.4.2.3. By End User
  • 5.3.5. South Korea Alpha Thalassemia Treatment Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By Treatment
      • 5.3.5.2.3. By End User

6. Europe Alpha Thalassemia Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Alpha Thalassemia Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By End User
  • 6.3.2. Germany Alpha Thalassemia Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By End User
  • 6.3.3. Spain Alpha Thalassemia Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By End User
  • 6.3.4. Italy Alpha Thalassemia Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Treatment
      • 6.3.4.2.3. By End User
  • 6.3.5. United Kingdom Alpha Thalassemia Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Treatment
      • 6.3.5.2.3. By End User

7. North America Alpha Thalassemia Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Alpha Thalassemia Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By End User
  • 7.3.2. Mexico Alpha Thalassemia Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By End User
  • 7.3.3. Canada Alpha Thalassemia Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By End User

8. South America Alpha Thalassemia Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Alpha Thalassemia Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By End User
  • 8.3.2. Argentina Alpha Thalassemia Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By End User
  • 8.3.3. Colombia Alpha Thalassemia Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By End User

9. Middle East and Africa Alpha Thalassemia Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Alpha Thalassemia Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By End User
  • 9.3.2. Saudi Arabia Alpha Thalassemia Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By End User
  • 9.3.3. UAE Alpha Thalassemia Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By End User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Alpha Thalassemia Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Agios Pharmaceuticals, Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Actis Technologies
• 14.3. Novartis Pharmaceuticals Corporation
• 14.4. Global Calcium PVT LTD
• 14.5. CHIESI Farmaceutici S.p.A.
• 14.6. Taro Pharmaceutical Industries Ltd.
• 14.7. Amgen Inc.
• 14.8. Sun Pharmaceutical Industries Ltd.
• 14.9. FRESENIUS SE & Co. KGaA
• 14.10.Acceleron Pharma.

15. Strategic Recommendations

16. About Us & Disclaimer